Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: A proof-of-concept study

Edoardo Gronda, Gino Seravalle, Gianmaria Brambilla, Giuseppe Costantino, Andrea Casini, Ali Alsheraei, Eric G. Lovett, Giuseppe Mancia, Guido Grassi

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF.

and results In a single-centre, open-label evaluation, patients with NYHA class III HF, EF

Conclusion BAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.

Original languageEnglish
Pages (from-to)977-983
Number of pages7
JournalEuropean Journal of Heart Failure
Volume16
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Baroreflex
Heart Failure
Hemodynamics
Therapeutics
Carotid Sinus
Electric Stimulation
Hypertension
Equipment and Supplies
Mortality

Keywords

  • Baroreflex
  • Heart failure
  • Non-pharmacological therapy
  • Sympathetic nervous system

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure : A proof-of-concept study. / Gronda, Edoardo; Seravalle, Gino; Brambilla, Gianmaria; Costantino, Giuseppe; Casini, Andrea; Alsheraei, Ali; Lovett, Eric G.; Mancia, Giuseppe; Grassi, Guido.

In: European Journal of Heart Failure, Vol. 16, No. 9, 2014, p. 977-983.

Research output: Contribution to journalArticle

Gronda, Edoardo ; Seravalle, Gino ; Brambilla, Gianmaria ; Costantino, Giuseppe ; Casini, Andrea ; Alsheraei, Ali ; Lovett, Eric G. ; Mancia, Giuseppe ; Grassi, Guido. / Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure : A proof-of-concept study. In: European Journal of Heart Failure. 2014 ; Vol. 16, No. 9. pp. 977-983.
@article{ee9599c4b1554d4f911d11c63d467789,
title = "Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: A proof-of-concept study",
abstract = "Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF.and results In a single-centre, open-label evaluation, patients with NYHA class III HF, EF Conclusion BAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.",
keywords = "Baroreflex, Heart failure, Non-pharmacological therapy, Sympathetic nervous system",
author = "Edoardo Gronda and Gino Seravalle and Gianmaria Brambilla and Giuseppe Costantino and Andrea Casini and Ali Alsheraei and Lovett, {Eric G.} and Giuseppe Mancia and Guido Grassi",
year = "2014",
doi = "10.1002/ejhf.138",
language = "English",
volume = "16",
pages = "977--983",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "9",

}

TY - JOUR

T1 - Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure

T2 - A proof-of-concept study

AU - Gronda, Edoardo

AU - Seravalle, Gino

AU - Brambilla, Gianmaria

AU - Costantino, Giuseppe

AU - Casini, Andrea

AU - Alsheraei, Ali

AU - Lovett, Eric G.

AU - Mancia, Giuseppe

AU - Grassi, Guido

PY - 2014

Y1 - 2014

N2 - Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF.and results In a single-centre, open-label evaluation, patients with NYHA class III HF, EF Conclusion BAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.

AB - Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device-based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF.and results In a single-centre, open-label evaluation, patients with NYHA class III HF, EF Conclusion BAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.

KW - Baroreflex

KW - Heart failure

KW - Non-pharmacological therapy

KW - Sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=84908242972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908242972&partnerID=8YFLogxK

U2 - 10.1002/ejhf.138

DO - 10.1002/ejhf.138

M3 - Article

C2 - 25067799

AN - SCOPUS:84908242972

VL - 16

SP - 977

EP - 983

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 9

ER -